The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Evox Therapeutics enters partnership to evaluate new gene editing technology for Rett Syndrome

27 Feb 2026

Evox Therapeutics, a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, has announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the company’s ExoEdit® exosome-based delivery platform to enable the development of a gene editing treatment for Rett syndrome. Rett syndrome is a... Read more

Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics

27 Feb 2026

Boehringer has acquired an exclusive license for a preclinical, small molecule program from Sitryx, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, based at The Oxford Science Park. The deal includes upfront and milestone payments to Sitryx totaling over US $500 million, plus tiered royalties. The program offers a novel, oral, potentially... Read more

CyanoCapture to build world's first robotic GMP facility for oral peptides with Persist AI

25 Feb 2026

CyanoCapture, the innovator in cyanobacteria-based oral drug delivery, and Persist AI, the leader in AI-driven robotic pharmaceutical formulation, have announced a strategic collaboration to jointly build a next-generation GMP manufacturing facility in the San Francisco Bay Area. The facility, expected to be operational later this year, will be the first of its kind to combine cyanobacteria culture and processing with robotic automation for... Read more

Scancell gets FDA approval to move into final-stage trial for new melanoma treatment

26 Jan 2026

Scancell has received approval from the US Food and Drug Administration (FDA) to begin a large, late-stage clinical trial of its skin cancer treatment, iSCIB1+ Immunobody®. The Phase 3 trial, which is planned to start this year, will test whether iSCIB1+ can help people with advanced melanoma live longer without their cancer getting worse. Results from Scancell’s earlier Phase 2 study are very encouraging. Patients who received iSCIB1+... Read more

Oxford Nanopore receives regulatory approval for its first diagnostic device in the UK and Europe

13 Jan 2026

Oxford Nanopore Technologies has announced that the GridION™ Dx is now both CE and UKCA marked, making it the company’s first In Vitro Diagnostic (IVD) device registered in the UK and Europe. The CE and UKCA certification confirms that GridION Dx meets stringent international standards for quality, safety, and performance, positioning Oxford Nanopore for future adoption in regulated clinical markets and reflecting its long-term commitment to... Read more

News